The Effect of a Probiotic on Hepatic Steatosis

Status Terminated

Clinical Trial Summary

Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States. The exact cause of NAFLD is unknown, but it is more common among people with conditions such as adult-onset diabetes. NAFLD can strike people of all ages but most often affects adults between the ages of 40 and 60. Research indicates that overgrowth of gut bacteria can start a chain of biological processes that stress the liver, causing liver inflammation. Probiotics, living bacteria taken orally, may decrease the stress on the liver by reducing this bacterial overgrowth and/or strengthening the gut walls. Because probiotics are generally safe, inexpensive, and easy to tolerate they are an attractive treatment option for NAFLD.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Fatty Liver

Clinical Trial Details

NCT number	NCT00099723
Study type	Interventional
Source	VSL Pharmaceuticals
Contact
Status	Terminated
Phase	Phase 1
Start date	October 2004
Completion date	December 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05979779` - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis	Phase 2
Recruiting	`NCT06051669` - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting	`NCT05984745` - Effect of CoQ10 on the Outcome of MAFLD Patients	Phase 2
Completed	`NCT02565446` - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram	N/A
Not yet recruiting	`NCT01694342` - Telomere Parameters in Patients With Nonalcoholic Fatty Liver	N/A
Completed	`NCT01464801` - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease	N/A
Completed	`NCT01992809` - Omega 3 Supplementation in Fatty Liver	Phase 3
Completed	`NCT00063635` - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)	Phase 3
Completed	`NCT00244569` - Development of a Breath Test for Monitoring Patients With Liver Disease	Phase 3
Recruiting	`NCT03972319` - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study	Early Phase 1
Completed	`NCT03141008` - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Recruiting	`NCT05125757` - Lifestyle Modification in Psoriatic Patients With Fatty Liver	N/A
Recruiting	`NCT05370053` - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology	N/A
Recruiting	`NCT04371042` - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed	`NCT04004273` - Diabetes, Exercise and Liver Fat (DELIVER)	N/A
Completed	`NCT02520609` - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting	`NCT02265276` - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease	Phase 3
Completed	`NCT02347007` - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults	N/A
Completed	`NCT01934777` - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis	Phase 3